首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model
【2h】

Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model

机译:表征三种二氨基嘧啶作为P2X3和P2X2 / 3受体的有效和选择性拮抗剂在疼痛模型中具有体内功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND AND PURPOSEP2X3 and P2X2/3 receptors are highly localized on the peripheral and central pathways of nociceptive signal transmission. The discovery of A-317491 allowed their validation as chronic inflammatory and neuropathic pain targets, but this molecule has a very limited oral bioavailability and CNS penetration. Recently, potent P2X3 and P2X2/3 blockers with a diaminopyrimidine core group and better bioavailability were synthesized and represent a new opportunity for the validation of P2X3-containing receptors as targets for pain. Here we present a characterization of three representative diaminopyrimidines.
机译:背景和PURPOSEP2X3和P2X2 / 3受体高度定位在伤害性信号传输的外围和中央路径上。 A-317491的发现使它们可以作为慢性炎症和神经性疼痛的靶标,但该分子的口服生物利用度和CNS渗透能力非常有限。最近,合成了具有二氨基嘧啶核心基团和更好的生物利用度的有效P2X3和P2X2 / 3阻滞剂,为验证含P2X3受体作为疼痛靶点提供了新的机会。在这里,我们介绍了三个代表性的二氨基嘧啶的表征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号